CRIP2

CRIP2 (also known as CSRP2/CRP2) is a dual-LIM-domain adaptor protein that functions in both the cytoplasm and nucleus to coordinate actin cytoskeleton organization and transcriptional regulation. Its two structurally independent LIM domains enable simultaneous engagement of multiple partners: CRIP2 directly binds and bundles F-actin filaments to stabilize stress fibres and invadopodia actin cores (PMID:14741346, PMID:26883198), and it assembles transcriptional complexes with SRF, GATA factors, MRTF-A/B, and the Brg1/SWI-SNF chromatin-remodeling complex to activate smooth muscle cell gene programs (PMID:12530967, PMID:17185421, PMID:37164693). CRIP2 also functions as a transcriptional repressor by interacting with NF-κB/p65 to suppress proangiogenic cytokine expression and with HOXA9 to impede HIF-1α-dependent glycolytic gene transcription (PMID:21540330, PMID:29662084). Its expression is regulated by TGF-β/ALK5/Smad signaling and p38 MAPK (PMID:16735029, PMID:37899269), and nuclear copper transfer from Atox1 induces a conformational change that targets CRIP2 for ubiquitin-mediated proteasomal degradation (PMID:34550632).

1. 1997 High

   Determining how LIM domains are organized was essential for understanding CRIP2's adaptor function; NMR revealed that each LIM domain folds into two independent zinc-binding modules with a conserved intermodular interface, and full-length CRP2 has two structurally autonomous LIM domains with no fixed relative orientation, establishing the structural basis for simultaneous multi-partner engagement.

   Evidence Multidimensional NMR spectroscopy of quail CRP2 LIM2 domain and full-length protein with 15N relaxation dynamics

   PMID:9115265 PMID:9722554

   Open questions at the time

   • No co-crystal or cryo-EM structure with any binding partner
   • How flexibility is constrained upon partner binding is unknown
2. 1998 Medium

   The question of what directs CRIP2's preferential expression in vascular smooth muscle was answered by identifying Sp1-dependent basal promoter elements and VSMC-specific regulatory regions in the 5′-flanking sequence.

   Evidence Deletion/EMSA analysis and lacZ-reporter transgenic mice

   PMID:9553112

   Open questions at the time

   • Identity of the VSMC-specific trans-acting factors beyond Sp1 is unknown
   • Enhancer elements for non-vascular expression contexts not mapped
3. 2003 High

   A key question was whether CRIP2 acts in transcription or only at the cytoskeleton; discovery that CRP2 bridges SRF and GATA proteins to activate smooth muscle gene promoters — and that dominant-negative CRP2 blocks smooth muscle differentiation — established CRIP2 as a transcriptional co-activator essential for smooth muscle cell fate.

   Evidence Co-immunoprecipitation, transcriptional reporter assays, dominant-negative mutant blocking proepicardial cell differentiation

   PMID:12530967

   Open questions at the time

   • Whether CRP2 contacts DNA directly or only acts through protein–protein bridging was not resolved
   • Relative contribution of LIM1 vs LIM2 to SRF vs GATA binding not fully dissected
4. 2004 High

   Whether CRIP2 has a direct cytoskeletal function independent of other actin-binding proteins was unclear; in vitro co-sedimentation showed that CRP2 autonomously binds F-actin and decorates stress fibres independently of α-actinin or zyxin, establishing a direct actin-stabilizing role.

   Evidence Recombinant protein F-actin co-sedimentation assay and GFP live-cell imaging in smooth muscle cells

   PMID:14741346

   Open questions at the time

   • Actin-binding interface on CRP2 not mapped
   • Whether CRP2 bundles or merely side-binds actin was not yet determined
5. 2006 High

   How CRIP2 activates smooth muscle genes at the chromatin level was unknown; the finding that CRP2 recruits Brg1/SWI-SNF to SRF-occupied smooth muscle gene promoters and promotes histone acetylation revealed a chromatin-remodeling mechanism, while TGF-β/ALK5/Smad signaling was identified as an upstream transcriptional inducer of CRP2 expression.

   Evidence Transgenic mice, protein transduction, ChIP for Brg1 and histone acetylation; pharmacological ALK5 inhibition (SB-431542) in smooth muscle and hepatic stellate cells

   PMID:16735029 PMID:17185421

   Open questions at the time

   • Whether Brg1 binds CRP2 directly or through SRF is unresolved
   • Smad-responsive elements in the CRIP2 promoter not mapped
6. 2008 Medium

   The in vivo requirement for CRIP2 was tested by gene knockout; Csrp2-deficient mice showed cardiomyocyte hypertrophy and mislocalization of intercalated disc proteins (β-catenin, N-RAP, connexin-43), confirming a bimodal cytoplasm/nucleus distribution and a role in cardiac cell architecture.

   Evidence Gene-targeted Csrp2 knockout mouse with electron microscopy and immunofluorescence

   PMID:18713466

   Open questions at the time

   • Mechanism connecting CRP2 loss to intercalated disc remodeling is unknown
   • No overt vascular smooth muscle phenotype was described despite high VSMC expression
7. 2011 High

   Whether CRIP2 functions as a transcriptional repressor was unknown; the demonstration that CRIP2 interacts with NF-κB/p65 to block its binding at IL6, IL8, and VEGF promoters revealed a tumor-suppressive repressor function distinct from its smooth muscle co-activator role.

   Evidence Co-IP, ChIP, and in vivo xenograft tumorigenesis assays with re-expression complementation in nasopharyngeal carcinoma cells

   PMID:21540330

   Open questions at the time

   • Whether CRP2 competes with NF-κB co-activators or directly modifies p65 is unclear
   • Generalizability beyond nasopharyngeal carcinoma not established
8. 2016 High

   Beyond stress fibre association, CRIP2's ability to actively organize actin architecture was demonstrated by showing that purified CRP2 autonomously crosslinks actin filaments into thick bundles and localizes to invadopodia actin cores, with CRP2 knockdown reducing ECM degradation and lung metastasis.

   Evidence Recombinant protein actin bundling assay, siRNA knockdown, ECM degradation assay, and xenograft lung metastasis model in breast cancer cells

   PMID:26883198

   Open questions at the time

   • Bundling stoichiometry and geometry not determined
   • Whether bundling and transcriptional activities are separable in cancer cells is untested
9. 2018 High

   A second transcriptional repressor mechanism was identified: HOXA9 recruits CRIP2 to glycolytic gene promoters (HK2, GLUT1, PDK1) to occlude HIF-1α binding, establishing CRIP2 as a metabolic brake on glycolysis in squamous cell carcinoma.

   Evidence Co-IP, ChIP at glycolytic gene promoters, promoter reporters, in vitro and in vivo glycolysis measurements

   PMID:29662084

   Open questions at the time

   • Whether CRIP2 directly contacts DNA at these promoters or acts solely via HOXA9 is unclear
   • Applicability to non-cancer metabolic regulation unknown
10. 2021 High

    How CRIP2 protein levels are regulated post-translationally was unknown; Atox1 was found to transfer copper to CRIP2 in the nucleus, inducing a secondary structure change that triggers ubiquitin-mediated proteasomal degradation, linking copper homeostasis to CRIP2 stability and downstream ROS/autophagy control.

    Evidence APEX2 proximity labeling, mass spectrometry, Co-IP, copper transfer assay, secondary structure analysis, proteasome inhibition, ROS and autophagy assays

    PMID:34550632

    Open questions at the time

    • Identity of the E3 ubiquitin ligase is unknown
    • Which CRIP2 zinc-binding sites accept copper is not mapped
    • Whether copper-induced degradation occurs in vivo is not confirmed
11. 2023 High

    The identity of the co-activator linking CRIP2 to the myocardin-related transcription factor pathway was resolved: CRIP2 directly binds MRTF-A and MRTF-B via specific polar residues in the C-terminal LIM domain to stabilize the MRTF/SRF/CArG-box complex; CRP2BP acts as a scaffolding adaptor (independent of its HAT activity) to enhance this complex, and p38 MAPK positively regulates CRIP2 expression.

    Evidence Co-IP with systematic mutagenesis, 3D structural analysis, siRNA knockdown, p38 MAPK inhibitor epistasis in myofibroblasts

    PMID:37164693 PMID:37899269

    Open questions at the time

    • Whether MRTF binding and actin bundling are mutually exclusive is untested
    • Whether p38 MAPK acts on CRIP2 promoter or mRNA stability is unknown
12. 2025 Medium

    CRIP2's cytoskeletal role in endothelial cells was clarified: CRIP2 interacts with KRT8 and VIM to maintain cytoskeleton integrity and normal adhesion, and its loss disrupts VEGFA/CDC42 and PDGF/JAK/STAT/SRF signaling, impairing endothelial migration and proliferation, while in zebrafish, CRIP2 suppresses Notch signaling through NF-κB in hemogenic endothelium to enable hematopoietic stem cell specification.

    Evidence Co-IP in HUVECs, siRNA knockdown, zebrafish CRISPR knockout, scRNA-seq, Notch inhibitor rescue epistasis

    PMID:40074973 PMID:41601327

    Open questions at the time

    • Whether CRIP2–NF-κB interaction in hemogenic endothelium uses the same mechanism as in cancer cells is unknown
    • Mammalian hematopoietic phenotype of CRIP2 loss not examined
    • KRT8/VIM interactions not validated by reciprocal pull-down

• Key open questions include: the structural basis of CRIP2's simultaneous engagement of actin and transcriptional partners, the identity of the E3 ligase mediating copper-dependent degradation, whether actin-bundling and transcriptional functions are spatially or temporally segregated in vivo, and the mechanism by which CRIP2 modulates Notch signaling in mammalian hematopoiesis.
• No co-structure of CRIP2 with any binding partner exists
• E3 ligase for copper-triggered degradation unidentified
• Separation-of-function mutations distinguishing cytoskeletal and nuclear roles not generated